AMPK and Pulmonary Hypertension: Crossroads Between Vasoconstriction and Vascular Remodeling

Qiang Zhao, Ping Song and Ming-Hui Zou*

Center for Molecular and Translational Medicine, Georgia State University, Atlanta, GA, United States

Pulmonary hypertension (PH) is a debilitating and life-threatening disease characterized by increased blood pressure within the pulmonary arteries. Adenosine monophosphate-activated protein kinase (AMPK) is a heterotrimeric serine-threonine kinase that contributes to the regulation of metabolic and redox signaling pathways. It has key roles in the regulation of cell survival and proliferation. The role of AMPK in PH is controversial because both inhibition and activation of AMPK are preventive against PH development. Some clinical studies found that metformin, the first-line antidiabetic drug and the canonical AMPK activator, has therapeutic efficacy during treatment of early-stage PH. Other study findings suggest the use of metformin is preferentially beneficial for treatment of PH associated with heart failure with preserved ejection fraction (PH-HFpEF). In this review, we discuss the “AMPK paradox” and highlight the differential effects of AMPK on pulmonary vasoconstriction and pulmonary vascular remodeling. We also review the effects of AMPK activators and inhibitors on rescue of preexisting PH in animals and include a discussion of gender differences in the response to metformin in PH.

Keywords: AMPK, pulmonary hypertension, pulmonary vascular remodeling, hypoxic pulmonary vasoconstriction, metformin

INTRODUCTION

Pulmonary hypertension (PH) is a disease characterized by high blood pressure that affects the vessels in lungs. These changes result in right ventricular failure and ultimately, premature death (Maron and Leopold, 2015). Adenosine monophosphate-activated protein kinase (AMPK) is a central regulator of energy homeostasis. It is activated under a variety of conditions, including hypoxia, nutrient starvation, and toxin exposure (Towler and Hardie, 2007; Kim et al., 2016; Herzig and Shaw, 2018). AMPK exerts most of its biological effects via catalytic α-subunits (α1 and α2) that are ubiquitously expressed in pulmonary vessels (Mihaylova and Shaw, 2011; Hardie, 2013; Kim et al., 2016). AMPK α1 is the predominant subunit in small pulmonary artery-derived pulmonary microvascular endothelial cells (ECs) and vascular smooth muscle cells (VSMCs). AMPK α2 is the predominant subunit in conduit pulmonary artery-derived ECs and VSMCs (Evans et al., 2005; Creighton et al., 2011). The AMPK α1 and AMPK α2 subunits have different effects on survival of pulmonary VSMCs and hypoxic pulmonary vasoconstriction. For example, activation of AMPK α1 stimulates autophagy in pulmonary artery VSMCs, but AMPK α2 activation prevents apoptosis...
(Ibe et al., 2013). Under conditions of mild hypoxia, AMPK α1 is activated by liver kinase B1 (LKB1) and is required for hypoxic pulmonary vasoconstriction; the AMPK α2 subunit is required under conditions of severe hypoxia (Moral-Sanz et al., 2018). Because of these characteristics, studies found that use of AMPK-targeting agonists and antagonists results in contradictory effects on PH development. Some studies found that AMPK activators [i.e., metformin (Agard et al., 2009; Dean et al., 2016; Lai et al., 2016; Omura et al., 2016; Zhai et al., 2018; Zhang et al., 2018; Wang et al., 2020), 5-aminoimidazole-4-carboxamide (AICAR) (Huang et al., 2014; Chen et al., 2016; Dean et al., 2016), rosiglitazone/pioglitazone (Hansmann et al., 2007; Satoh et al., 2009; Kim et al., 2010; Legchenko et al., 2018), and apelin (Chandra et al., 2011; Kim et al., 2014)] are protective against experimental PH. Other studies found that AMPK activation induces hypoxic pulmonary vasoconstriction (Evans, 2006; Robertson et al., 2008; Evans et al., 2009; Moral-Sanz et al., 2018) and that inhibition of AMPK by compound C prevents PH (Ibe et al., 2013). Results from human clinical studies are not currently conclusive on the precise role of AMPK in PH because studies on PH treatment using metformin are currently phase two clinical trials (NCT01884051 and NCT03629340). The AMPK paradoxe remains relevant.

AMPK: STRUCTURE AND REGULATION

AMPK Structure

Adenosine monophosphate-activated protein kinase is a highly conserved serine/threonine protein kinase complex consisting of a catalytic α-subunit, a scaffolding β-subunit, and a regulatory γ-subunit (Figure 1). In eukaryotes, each subunit has multiple distinct isoforms encoded by different genes. The α-subunit has two isoforms, α1 and α2, encoded by genes Prkaa1 and Prkka2, respectively (Stapleton et al., 1996). It contains a canonical N-terminal Ser/Thr kinase domain (KD), an auto-inhibitory domain (AID), and an adenine nucleotide sensor segment termed an α-linker (Herzig and Shaw, 2018; Yan et al., 2018). AMPK activation requires phosphorylation of critical residues (Thr174 in the AMPK α1 subunit and Thr172 in the AMPK α2 subunit) within the activation loop of the KD in the AMPKα catalytic subunit that is phosphorylated by upstream kinases LKB1 (Hudson et al., 2003), Ca²⁺/calmodulin-dependent protein kinase β (CaMKKβ) (Woods et al., 2005), or TGF-beta-activated kinase-1 (TAK-1) (Momcilovic et al., 2006). AMPK auto-inhibition requires an AID, which interacts with the KD and causes AMPK to be maintained as an inactive conformation (Chen et al., 2013; Kim et al., 2016). The β-subunit also has two isoforms, β1 and β2, encoded by Prkab1 and Prkab2, respectively (Hudson et al., 2003). The γ-subunit has three isoforms, γ1, γ2, and γ3, encoded by Prkg1, Prkg2, and Prkg3, respectively (Cheung et al., 2000). The γ-subunits contain four tandem cystathionine-β-synthase domains, which enable AMP, ATP, or ADP binding (Xiao et al., 2007). Binding of AMP, and to a lesser extent ADP, to the γ-subunit is an important regulatory feature of the conformational switch that activates the AMPK complex (Hardie et al., 2011; Gowans et al., 2013; Ross et al., 2016a). Each AMPK complex consists of one α-subunit, one β-subunit, and one γ-subunit, and all 12 heterotrimeric combinations are possible (Ross et al., 2016b). Different subunits have distinct organ preferences and expression patterns. For example, the AMPK α1 subunit is mainly expressed in adipose tissue (Ruderman et al., 2003; Rutter et al., 2003; Kelly et al., 2004). The AMPK α2 subunit is predominantly expressed in skeletal muscle and cardiac myocytes (Sakamoto et al., 2005, 2006; Thomson et al., 2007). Isoform-specific roles of AMPK α1/AMPK α2 contribute to the pathogenesis of different diseases (e.g., cardiovascular disease (Ahmad et al., 2005; Sakamoto et al., 2006; Zarrinpashne et al., 2006; Arad et al., 2007), osteoclastogenesis (Wang et al., 2016), and Alzheimer’s disease (Zhao et al., 2020)).

AMPK Signaling Transduction

Adenosine monophosphate-activated protein kinase can be phosphorylated directly by small molecules that mimic cellular decreased ATP-to-ADP or ATP-to-AMP ratios or three upstream AMPK kinases (i.e., LKB1, CaMKKβ and TAK1) (Figure 1). Upon changes in ATP/ADP and ATP/AMP ratios that occur during nutrient starvation, AMP binds to the AMPK γ subunit to cause allosteric activation via modulation of the phosphorylation state of Thr172 (Xiao et al., 2011; Oakhill et al., 2012; Gowans et al., 2013). LKB1, in a complex with the pseudokinase STRAD and the scaffolding protein MO25, directly phosphorylates AMPK at Thr172 (Lizcano et al., 2004). Study results indicate that LKB1 is the principal route via which AMPK is activated in many organs (e.g., skeletal muscle, adipose tissue, and liver) (Shackelford and Shaw, 2009). Whereas, CaMKKβ activates AMPK in response to Ca²⁺ signaling pathways (Hawley et al., 2005; Hong et al., 2005; Hurley et al., 2005). In 2006, TAK1 (i.e., MAPKK kinase-7, MAP3K7) was identified as the third kinase capable of direct AMPK activation (Momcilovic et al., 2006).

Adenosine monophosphate-activated protein kinase can be activated by hypoxia in various tissue and cell types (Mungai et al., 2011; SallÈ-Lefort et al., 2016), but long-term hypoxia exposure inhibits AMPK activation (de Theije et al., 2018). Many studies found that activation of AMPK under hypoxia primarily implies LKB1 activity, because AMPK activation is abrogated in LKB1-deleted cells and knockout of CaMKK2, or another upstream kinase, has no effect on AMPK activation in VSMCs under hypoxic conditions (Moral-Sanz et al., 2018). Some studies found that LKB1 seems to only activate the AMPK α2 subunit, because the AMPK α1 subunit remains phosphorylated in LKB1-deficient heart muscle cells (Sakamoto et al., 2006). This result might be explained by differences in abundances and preferences of the AMPK upstream kinase in different cells and organs. Increased production of reactive oxygen species (ROS) in hypoxic conditions contributes to activation of AMPK (Choi et al., 2001; Emerling et al., 2009; Zmijewski et al., 2010; Hinchy et al., 2018). Hypoxia-inducible factor-prolyl-4-hydroxylases (HIF-4Hs) have a role in the activation of AMPK (Yan et al., 2012; Dengler and Gabel, 2019).

Once activated, AMPK phosphorylates key proteins in multiple pathways (Marsin et al., 2000; Inoki et al., 2003;
Zhao et al. AMPK and Pulmonary Hypertension

FIGURE 1 | Summary of AMP-activated protein kinase (AMPK) structure and activation. Domain structure of AMPK trimer: α-, β-, and γ-subunits with respective domains. AMPK α subunits: KD, kinase domain containing Thr-172 phosphorylation site; AID, autoinhibitory domain; BD, binding domain. AMPK β subunits: CBM, carbohydrate binding module; BD, binding domain. AMPK γ subunits: CBS, cystathionine-β-synthase domain. The upstream kinases LKB1, CAMKK2, and TAK1 are shown above the AMPK complex. LKB1 in complex with STRAD and MO25 activates AMPK; CAMKK2, activated by intracellular calcium.

Gwinn et al., 2008) or directly regulates key enzymes involved in these pathways. These processes occur over time via targeting of transcriptional regulators (Koo et al., 2005; Lamia et al., 2009; Bungard et al., 2010; Figure 1). The most important aspect of AMPK biology is its role in maintaining the balance between catabolism and anabolism in response to metabolic stress (Towler and Hardie, 2007; Hardie, 2008; Fogarty and Hardie, 2010). Studies have revealed the roles of AMPK in lipid homeostasis [e.g., acetyl-CoA carboxylase (Munday et al., 1988) and HMG-CoA reductase (Carling et al., 1987)], glucose metabolism [e.g., thio-redoxin-interacting protein (TXNIP) (Wu et al., 2013) and 6-phosphofructo-2-kinase (Bando et al., 2005)], insulin signaling (Galic et al., 2011; Li Y. et al., 2011; Fullerton et al., 2013; Wu et al., 2015; Emilio et al., 2016; Myers et al., 2017), and food intake and body weight (Kahn et al., 2005; Kola et al., 2005; Kola, 2008). Given those functional attributes in metabolism, AMPK is a major therapeutic target for treatment of metabolic diseases (e.g., type 2 diabetes) and obesity (Violet et al., 2009; Rojas et al., 2011; Hardie, 2013; Day et al., 2017). A growing body of evidence also points to specific regulation of AMPK and mitochondrial homeostasis, including via stimulation of mitochondrial biogenesis (Bergeron et al., 2001; Zong et al., 2002; Garcia-Roves et al., 2008), regulation of mitochondrial dynamics (Ducommun et al., 2015; Toyama et al., 2016), and mitophagy (Wang et al., 2001; Egan et al., 2011).

AMPK and Cardiovascular Disease
Adenosine monophosphate-activated protein kinase has pivotal roles in cardiovascular physiology and in cardiovascular disease states. AMPK α1 is the predominant subunit in VSMCs, ECs, monocytes/macrophages, and adipocytes. AMPK α2 is the predominant subunit in cardiomyocytes (Shirwany and Zou, 2010; Wu and Zou, 2020). The functions of AMPK in cardiovascular disease include contributions to atherosclerosis and to heart failure and hypertension, which have been extensively reviewed elsewhere (Shirwany and Zou, 2010; Wu and Zou, 2020).

PULMONARY HYPERTENSION
Categories
Pulmonary hypertension is a general term used to describe increased blood pressure (mean pulmonary arterial pressure, mPAP, exceeds 25 mmHg at rest) in the lungs (Galiè et al., 2009). At the 5th and 6th World Symposium on PH, it was classified into five groups: pulmonary artery hypertension (PAH, Group 1), PH associated with left heart disease (Group 2), PH associated with lung disease and/or hypoxia (Group 3), PH associated with chronic thromboembolic disease (Group 4), and PH with unclear or multifactorial mechanisms, or both (Group 5) (Galiè and Simonneau, 2013; Simonneau et al., 2019). Each group represents a very broad spectrum of disease etiology, pathobiology, hemodynamic characteristics, and therapeutic approaches (Table 1). The detailed features and treatments of pulmonary hypertensive vascular disease in humans have been reviewed elsewhere (Maron and Galiè, 2016; Thenappan et al., 2018). AMPK deficiency has been identified in metabolic syndrome-associated PH (PH-HFpE) (Lai et al., 2016). However, in PAH, AMPK activity and expression can be either inhibited or promoted depending on cell type and branch pulmonary artery diameter (Ibe et al., 2013; Omura et al., 2016; Zhang et al., 2018), which is discussed in section “Clinical Trials of Pulmonary Hypertension Treatment Using Metformin.”

Pathology of PH
Although the exact causes of PH remain to be determined, study findings indicate that it results from a combination of sustained pulmonary vasoconstriction and pulmonary vascular remodeling (Stenmark and McMurtry, 2005; Stenmark et al., 2006).
Pulmonary vasoconstriction is the major contributor to the early phase of the disease; pulmonary vascular structural remodeling becomes progressively more dominant and important over time (Shimoda and Laurie, 2013). Hypoxic pulmonary vasoconstriction is a reflex contraction of vascular smooth muscle in the pulmonary circulation to optimize lung blood flow from low ventilated areas to well-oxygenated areas, and thereby optimize gas exchange and oxygen delivery (Moudgil et al., 2005; Dunham-Snary et al., 2017; Tarry and Powell, 2017). Unlike the systemic circulation, which dilates in the presence of hypoxia, pulmonary arteries constrict in response to alveolar hypoxia (Detar, 1980; Waypa and Schumacker, 2010). Hypoxic pulmonary vasoconstriction is an important homeostatic mechanism used to match regional perfusion and ventilation in the lung (Dunham-Snary et al., 2017; Tarry and Powell, 2017).

Sustained pulmonary vasoconstriction initiates pulmonary vascular structural changes. These changes are characterized by thickening of the intimal and/or medial layers of muscular vessels, which results in concentric pulmonary vascular remodeling (Heath and Edwards, 1958; Tuder, 2017). In human beings, pulmonary vascular remodeling is attributed to lesions that mainly occur in distal pre-capillary arteries, ranging in diameter from 500 to 700 μm. Remodeling involves a change in the maximal lumen diameter (interior and exterior) and accumulation of different vascular cell types in the pulmonary arterial wall (pulmonary artery ECs, VSMCs, and fibroblasts). Pulmonary endothelial dysfunction is the key trigger that drives PH development. It is characterized by either impairment of endothelial-dependent vasodilatation, reduced anticoagulant properties, ROS production, or active EC metabolic changes (Budhiraja et al., 2004; Attinà et al., 2005; Klinger et al., 2013; Ranchoux et al., 2018). Various stimuli (e.g., hypoxia, smoking, disturbed blood flow, and oxidative stress) can lead to endothelial dysfunction (Dummer et al., 2018; Ranchoux et al., 2018). In PH, progressive accumulation of resident VSMCs in pulmonary arteries contributes to expansion of the tunica media. Accumulating evidence also supports involvement of increased VSMC proliferation and inhibition of apoptosis in pulmonary vascular medial layer thickening (Tuder et al., 2007; Lyle et al., 2017; Humbert et al., 2019). Better understanding of the molecular mechanisms underlying pulmonary endothelial dysfunction and VSMC adaptation will greatly enhance our understanding of the pathogenesis of PH, which may help identify new therapeutic strategies. Other promising targets (e.g., fibroblast cell activation and immune system dysregulation) have also been identified as contributing to the pathogenesis of PH (Li M. et al., 2011; Rabinovitch et al., 2014; Plecitá-Hlavatá et al., 2016; Nicolls and Voelkel, 2017).

### Animal Models of PH

A variety of pre-clinical PH animal models are available to study this complex disease of diverse etiologies and histopathological features. Each model has its own hemodynamic and microanatomic histological characteristics (Table 1). The chronic hypoxia rat/mouse model is the one most widely used to study PH. Exposure of rats/mice to hypoxia causes increased mPAP, pulmonary vasoconstriction, and vascular medial hypertrophy that mimic the pathological features of human PH. However, right ventricular failure is absent (Zhao, 2010; Ryan et al., 2013). Monocrotaline (MCT) is a toxic alkaloid that causes a widespread pneumotoxicity and endothelial injury (Kay et al., 1967; Wilson et al., 1989). A single dose of MCT (60 mg/Kg) is sufficient to induce PH in rats by modulating two key pathological features of human PH, pulmonary vascular remodeling and right ventricular failure (Schoental and Head, 1955; Jasmin et al., 2001; Dumarascu et al., 2008; Gomez-Arroyo et al., 2012). Sugen 5416 is a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. Sugen 5416/hypoxia (Su/Hx) induces severe PH in both rats and mice that is characterized by pulmonary angioobliteration and right ventricular failure (Taraseviceni-Stewart et al., 2001; Sakaö and Tatsumi, 2011). These three PH animal models are well-recognized models of Group 1 PH and Group 3 PH (Ryan et al., 2013; Colvin and Yeager, 2014; Sztuka and Jasińska-Stroschein, 2017). Lai et al. (2016) developed a two-hit model of PH associated with heart failure with preserved ejection fraction (PH-HFP EF). It includes giving a single injection of SU5416 to obese ZSF1 rats. The SU5416/obese ZSF1 rats develop PH that includes a preserved ejection fraction and right and left ventricular hypertrophy. PH-HFP EF develops as a more advanced corollary of PH and diastolic HF, leading to more severe symptoms than those with HFP EF and suffers significant exercise intolerance, frequent hospitalization, and reduced survival (Thenpam et al., 2011; Hoeper et al., 2016).

| Table 1 | Animal models of pulmonary hypertension. |
|---|---|
| **Cause** | **Histological features** | **Animal models** |
| **Group 1: Pulmonary arterial hypertension (PAH)** | | |
| Idiopathic PAH | Pulmonary artery intimal proliferation | Su-Hx rat/mouse |
| Heritable PAH | Pulmonary artery medial hypertrophy | MCT rat |
| Drugs/Toxin/Others | Pleomorphic lesions | Su-Hx-Normoxia |
| **Group 2: Pulmonary hypertension with left heart disease** | | |
| Left-sided heart disease | Pulmonary medical hypertrophy | SUG416/Obese |
| | Pulmonary vein arterioles | ZSF1 rat |
| | Pulmonary interstitial edema | |
| **Group 3: Pulmonary hypertension associated with lung disease and/or hypoxemia** | | |
| High altitudes | Hypoxic pulmonary vasoconstriction | Su-Hx rat/mouse |
| COPD/Pulmonary fibrosis | Muscularization of arterioles | Hypoxia rat/mouse |
| Obstructive sleep apnea | | |
| **Group 4: Pulmonary hypertension due to chronic thrombotic and/or embolic disease** | | |
| Pulmonary emboli | Thrombi or embolism | Vena cava ligation |
| Other clotting disorders | Recanalized organized thrombi | |
| **Group 5: Pulmonary hypertension triggered by other health conditions** | | |
| Heterogeneous | Heterogeneous |
AMPK AND PULMONARY HYPERTENSION

Role of AMPK in the Predisposition and Development of PH

Researches have revealed the role of AMPK in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Two clinical trials (NCT01884051 and NCT03629340) focusing on PAH treatment with metformin are in progress. However, in various animal models, AMPK has contradictory effects on PH, as both inhibition and activation of AMPK are protective for the development of PH. These seemingly opposing results can be partly explained by the different effects of AMPK signaling in pulmonary vasoconstriction and pulmonary vascular remodeling.

Role of AMPK in Hypoxic Pulmonary Vasoconstriction

Until 1871, it was universally believed that the pulmonary vessels did not respond to a vasomotor system. However, Brown-Séquard (1871) published some results indicating that such a system exists. Subsequently, Bradford and Dean (1894) reported that asphyxia causes PH. von Euler and von Liljestrand (1946) reported that acute hypoxia promotes pulmonary vasoconstriction to increase pulmonary arterial pressure. This study (von Euler and von Liljestrand, 1946) launched the current era of study of hypoxia and pulmonary vasoconstriction.

Hypoxic pulmonary vasoconstriction is an important homeostatic physiological mechanism that optimizes ventilation/perfusion matching, gas exchange, and systemic oxygen delivery. In response to alveolar hypoxia, intrapulmonary arteries constrict to divert blood to better-oxygenated lung segments (Bradford and Dean, 1894; von Euler and von Liljestrand, 1946; McMurtry et al., 1976; Madden et al., 1985; Sylvester et al., 2012; Dunham-Snary et al., 2017). Hypoxic pulmonary vasoconstriction relies on a group of specialized pulmonary VSMCs, which are located in pulmonary arterial segments stripped of the tunica intima and tunica media, but not in similar segments of pulmonary veins or systemic arteries (Bergofsky et al., 1967; Murray et al., 1990a,b; Madden et al., 1992; Weir and Archer, 1995). Hypoxic pulmonary vasoconstriction is triggered by mitochondrial redox signaling that involves voltage-gated potassium channels (Kv) and calcium channels (Weir and Archer, 1995). Hypoxia inhibits Kv channels in pulmonary VSMCs, causing membrane depolarization and opening of voltage-gated calcium channels to initiate Ca{sup 2+}-mediated pulmonary vasoconstriction (Weir and Archer, 1995; Archer and Michelakis, 2002; Sommer et al., 2008; Dunham-Snary et al., 2017).

Adenosine monophosphate-activated protein kinase has a critical role in hypoxic pulmonary vasoconstriction by linking the oxygen sensor to its effectors (Figure 2). Evans et al. (2005, 2006) and Evans (2006) found that physiological hypoxia increases the AMP/ATP ratio in pulmonary VSMCs, followed by increased AMPK activity and phosphorylation of a classical AMPK substrate, acetyl CoA carboxylase (a well-validated marker for AMPK activation). This process is likely to be mediated by binding of AMP to the AMPK γ subunit, which triggers activation of the kinase by, (1) promoting AMPK Thr 172 phosphorylation via allosteric regulation (Scott et al., 2002; Kemp, 2004; Oakhill et al., 2010), (2) inhibiting AMPK Thr 172 dephosphorylation (Davies et al., 1995), and (3) facilitating phosphorylation of Thr 172 by the upstream kinase LKB1 (Hawley et al., 2003; Woods et al., 2003; Shaw et al., 2004, 2005). Additional studies found that AMPK activation evokes a slow, sustained, and reversible increase in Ca{sup 2+} influx via cyclic adenosine diphosphate-ribose (cADPR)-dependent mobilization of sarcoplasmic reticulum stores in pulmonary VSMCs and the consequent induction of constriction of pulmonary artery rings (Evans et al., 2005). Consistent with these findings, two different AMPK activators, AICAR and phenformin, evoke intracellular Ca{sup 2+} influx and reversible constriction of the pulmonary artery rings. The characteristics of this process are strikingly similar to those of hypoxic pulmonary vasoconstriction (Evans et al., 2005). The hypoxia-associated pulmonary vasoconstriction and Ca{sup 2+} influx is inhibited by the non-selective AMPK antagonist, compound C, upon inhibition of the sarcoplasmic reticulum store-refilling current (Robertson et al., 2008). When hypoxia occurs, AMPK can directly phosphorylate voltage-gated potassium channels (Kv1.5 channels), followed by inhibition of K{sup +} currents in pulmonary VSMCs. The entry of voltage-dependent Ca{sup 2+} to initiate the hypoxia-related pulmonary vasoconstriction is thus activated (Moral-Sanz et al., 2016). Downregulation of Kv1.5 expression and activity is also a hallmark of PH (Yuan et al., 1998; Lv et al., 2013). Strong support for this mechanism results from in vivo studies performed by Moral-Sanz et al. (2018), who found a key in vivo role of AMPK in hypoxic pulmonary vasoconstriction using a combination of AMPK isofrom deletion strategies and spectral Doppler ultrasound. Under conditions of mild hypoxia (8% O{sub 2}), deletion of AMPK α1, but not AMPK α2, in smooth muscle cells block induction of hypoxia-related pulmonary vasoconstriction. When conditions of severe hypoxia (5% O{sub 2}) are present, either AMPK α1 or AMPK α2 deletion attenuates hypoxia-related pulmonary vasoconstriction (Moral-Sanz et al., 2018). The findings that SNPs in the Prkaa1 gene have been identified in populations that live at high altitudes and who have attenuated hypoxic pulmonary vasoconstriction are consistent with these results (Penaloza and Arias-Stella, 2007; Bigham et al., 2014). In summary, a growing body of evidence supports the hypothesis that AMPK activation is a primary mediator of hypoxic pulmonary vasoconstriction.

Role of AMPK in Pulmonary Vasculature Remodeling

In PH, pulmonary arteries and veins undergo structure changes. This pulmonary vascular remodeling is characterized by proliferation of pulmonary ECs and VSMCs. AMPK has a key role in the pathogenesis of pulmonary vasculature remodeling (Figure 3).

AMPK in Endothelial Cells and PH

Both AMPK subunits (AMPK α1 and AMPK α2) are expressed in pulmonary ECs. However, AMPK α1 is mainly expressed in capillary-derived pulmonary microvascular ECs and AMPK α2 is mainly expressed in conduit-derived pulmonary artery ECs.
AMPK in Vascular Smooth Muscle Cells and PH

During PH development, the remodeling process universally involves medial thickening driven by VSMC proliferation/hypertrophy and deposition of extracellular matrix within the tunica media of pulmonary arteries (Lyle et al., 2017). Pulmonary VSMCs express both the AMPK α1 and AMPK α2 subunits of AMPK (Creighton et al., 2011; Ibe et al., 2013). However, AMPK α1 is the predominant subunit in pulmonary VSMCs and contributes up to 80% of total AMPK activity (Evans et al., 2005; Xue et al., 2017). AMPK α1 catalytic activity is much higher in VSMCs from small pulmonary arteries than in those from the main pulmonary arteries (Evans et al., 2005). Unlike AMPK in pulmonary ECs, studies of AMPK in pulmonary VSMCs have found contradictory results. Some studies found that phosphorylated AMPK is increased, while total AMPK levels remain the same, in pulmonary VSMCs from pulmonary hypertensive patients and hypoxia-induced PH mice, compared with those from healthy donors or non-PH mice, respectively (Krymskaya et al., 2011; Ibe et al., 2013). Mechanistically, hypoxia-activated AMPK promotes pulmonary VSMC survival, but AMPK activity pharmacologically inhibited by either compound C or 9-β-d-arabinofuranosyl adenine (Ara-a) abrogates hypoxia-induced pulmonary VSMC proliferation and PH (Ibe et al., 2013; Xue et al., 2017). Ibe et al. (2013) found that although suppression of either AMPK α1 or α2 in pulmonary VSMCs leads to increased cell death, AMPK α1 and AMPK α2 have differential roles. Activation of AMPK α1 stimulates autophagy and promotes pulmonary VSMC survival; activation of AMPK α2 regulates myeloid cell leukemia sequence 1 (MCL-1) to prevent apoptosis (Ibe et al., 2013). In contrast to these results, another series of studies found that phosphorylated AMPK is decreased in pulmonary VSMCs from patients with PH and from mice with hypoxia-induced PH, compared with those from healthy donors or non-PH mice, respectively (Goncharov et al., 2014). AMPK inhibition promotes pulmonary VSMC proliferation and survival, but AMPK pharmacologically activated by metformin or AICAR inhibits hypoxia-induced pulmonary VSMC proliferation and chronic PH (Agard et al., 2009; Goncharov et al., 2014; Wu et al., 2014; Ke et al., 2016; Song et al., 2016; Gui et al., 2017; Liu et al., 2019). Seemingly contradictory results should be interpreted with caution. In the study that found elevated AMPK phosphorylation in PH and AMPK inhibition-attenuated
PH (Krymskaya et al., 2011; Ibe et al., 2013), the researchers used pulmonary VSMCs isolated from large-diameter arteries located in a segment of pulmonary arteries just proximal to where lung entry occurs (diameter ≥ 0.8 mm). In the study that found AMPK reduction in PH and PH mitigation by AMPK activation (Goncharov et al., 2014), pulmonary VSMCs isolated from small-diameter arteries located in distal pulmonary artery segments (type III, diameter ≤ 0.1 mm) were used. Therefore, these discrepancies may be due to different functions of AMPK or different AMPK isoforms, or both, in pulmonary arteries with different diameters. Hypoxic pulmonary vasoconstriction is more vigorous in small pulmonary arteries (Dawson et al., 1977; Grimm et al., 1978; Sylvester et al., 2012), where the AMPK α1 catalytic subunit is predominantly expressed (Evans et al., 2005). The non-selective nature of AMPK activators or inhibitors may be another factor that contributes to these apparent inconsistencies.

**AMPK and Pulmonary Hypertension Treatment**

**AMPK Inhibition Is Preventive for Development of Pulmonary Hypertension**

Ibe et al. (2013) found that inhibition of AMPK by compound C prevents development of hypoxia-induced PH. When mice treated with compound C one day before hypoxia exposure (10% oxygen for 3 weeks), compound C prevents hypoxia-induced PH, pulmonary arterial wall thickening, and right ventricular hypertrophy. The activation of AMPK α1 stimulates autophagy, promoting pulmonary VSMCs survival, whereas the activation of AMPK α2 increases the expression of myeloid cell leukemia sequence 1 (MCL-1), inhibiting pulmonary VSMCs apoptosis (Ibe et al., 2013). Consistent with these results, Robertson et al. (2008) and Evans et al. (2009) pre-incubated intrapulmonary arteries (3rd and 4th order branches of the pulmonary arterial tree, 0.2–0.5 mm internal diameter) with compound C (40 mM). Compound C reversed/inhibited hypoxic pulmonary vasoconstriction in a concentration-dependent manner. Functionally, AMPK phosphorylates voltage-gated K+ channel (Kv2.1) and thereby confers a leftward shift in both the activation and inactivation curves of Kv2.1, which precipitates an increase in the intracellular Ca^{2+} concentration (Evans et al., 2009).

**AMPK Activation Is Preventive for Development of Pulmonary Hypertension**

A significant body of evidence suggests that AMPK activation is preventive for development of PH. Metformin, the first-line medication for treatment of type 2 diabetes and the canonical
AMPK activator, demonstrates therapeutic efficacy on PH in animal models. AMPK activation by metformin prevents MCT-induced PH in rats (Agard et al., 2009; Li et al., 2016; Zhai et al., 2018; Sun et al., 2019; Yoshida et al., 2020). In these experimental models, rats were injected with one dose of MCT (60 mg/kg) to induce PH. Metformin (100–150 mg/kg/day, drinking water or intraperitoneal injection, 21–30 days) treatment significantly reduced right ventricular systolic pressure and pulmonary vascular remodeling in rats with MCT-induced PH (Agard et al., 2009; Li et al., 2016; Zhai et al., 2018; Sun et al., 2019; Yoshida et al., 2020). Consistent with these results, metformin has protective effects on hypoxia-induced PH in mice and rats (Huang et al., 2014; Omura et al., 2016; Liu et al., 2019), and a more pronounced PH with angioobliterative lesions in Sugen 5416/hypoxia (SuHx) mice/rats (Dean et al., 2016; Zhang et al., 2018) and SU5416/Obese ZSF1 rats (Lai et al., 2016; Wang et al., 2020). The AMPK activator, AICAR, also prevents PH development in rats with hypoxia-induced PH (Huang et al., 2014; Chen et al., 2016).

In contrast to the results that metformin has protective effects, other researchers reported that their findings did not support the efficacy of metformin in PH animal models (Goncharov et al., 2018). Goncharov et al. (2018) found no changes in right ventricular systolic pressure, right ventricular hypertrophy, or pulmonary vascular remodeling in the metformin-treated SuHx mice. They also evaluated the preventive effects of metformin and AICAR in PAH. In these animal models, metformin (300 mg/kg/day, drinking water, 42 days) or AICAR (500 mg/kg/day, intraperitoneal, 42 days) were administrated 1 day before SuHx exposure. They found no changes in right ventricular systolic pressure, right ventricular hypertrophy, or pulmonary vascular remodeling in either the metformin- or AICAR-treated SuHx rats. However, they did not measure phosphorylation levels of AMPK or downstream AMPK pathways. Metformin-induced AMPK activation requires full activation of an upstream kinase (e.g., LKB1), especially at low doses (Choi et al., 2001; Emerling et al., 2009; Zmijewski et al., 2010; Hinchy et al., 2018). Therefore, it is unknown whether the lack of metformin efficacy for PH treatment was associated with AMPK activation.

Different characteristics that likely contribute to apparently contradictory results are presented in Table 2. In Dean et al. (2016), AMPK activation by metformin (100 mg/kg/day, oral gavage, 21 days) seems to reverse the PH phenotype induced by SuHx in female rats, in contrast to the findings of Goncharov et al. (2018) that was performed using male rats. Thus, a sex difference might affect the response to metformin treatment of PH. Effects of this difference have been described for other diseases (e.g., obesity, aging, and spontaneous tumorigenesis) (Anisimov et al., 2010; Quan et al., 2016; Park et al., 2017; Bramante et al., 2021).

### Clinical Trials of Pulmonary Hypertension Treatment Using Metformin

There has been significant interest in the use of metformin for PH treatment. Liao et al. (2018, 2019) found that a combination therapy using metformin (500 mg, twice daily, 3 months) and bosentan (endothelin receptor antagonist) improves 6-min walk distance and right heart hemodynamics, decreases serum pro-brain natriuretic peptide (pro-BNP) levels, and ameliorates pulmonary vasoconstriction in patients with PH associated with congenital heart defects. Two phase I/II clinical trials of

---

**Table 2** Pulmonary hypertension (PH) animal experiments of AMPK.

| Therapy                        | Dose (mg/kg/day) | Route | Time (day) | PH models | Sex | References                          |
|-------------------------------|-----------------|-------|------------|-----------|-----|-------------------------------------|
| **AMPK activator with beneficial effects on PH** |                 |       |            |           |     |                                     |
| Metformin                     | 100–150         | p.o.  | 21–28      | MCT rat   | M   | Zhai et al., 2018; Yoshida et al., 2020 |
| Metformin                     | 100–150         | i.p.  | 21–28      | MCT rat   | M   | Agard et al., 2009; Li et al., 2016 |
| Metformin                     | 100             | i.p.  | 30         | MCT rat   | M   | Sun et al., 2019                    |
| Metformin                     | 100             | i.p.  | 21         | Hypoxia rat |     | Liu et al., 2019                   |
| Metformin                     | 100             | p.o.  | 21         | SuHx rat  | F   | Dean et al., 2016                   |
| Metformin                     | 300             | p.o.  | 31–28      | Obese ZSF1 rat | M | Lai et al., 2016 |
| Metformin                     | 300             | p.o.  | 98         | SU5416/Obese ZSF1 rat | F | Wang et al., 2020 |
| Metformin                     | 150             | i.p.  | 14         | SuHx mouse | M   | Zhang et al., 2018                  |
| Metformin                     | 100             | p.o.  | 21         | Hypoxia mouse | M   | Omura et al., 2016  |
| AICAR                         | 1?             | i.p.  | 28         | Hypoxia rat | M   | Huang et al., 2014; Chen et al., 2016 |
| **AMPK antagonist with beneficial effects on PH** |                 |       |            |           |     |                                     |
| Compound C                    | 20              | i.p.  | 21         | Hypoxia mouse | M   | Ibe et al., 2013 |
| **AMPK activators without effects on PH** |                 |       |            |           |     |                                     |
| Metformin                     | 100             | p.o.  | 14         | SuHx mouse | M   | Goncharov et al., 2018 |
| Metformin                     | 300             | p.o.  | 42         | SuHx rat  | M   | Goncharov et al., 2018 |
| AICAR                         | 500             | p.o.  | 42         | SuHx rat  | M   | Goncharov et al., 2018 |

p.o., oral administration (per os); i.p., intraperitoneal injection.
metformin for PH treatment are in progress (clinicaltrials.gov, NCT01884051 and NCT03629340). Results to date indicate good tolerability and potential clinical efficacy for improvement in right ventricular function in patients with PH who receive metformin therapy (2 g/day, 8 weeks) (Brittain et al., 2020). However, metformin use did not change the 6-min walk distance in those patients (Brittain et al., 2020). Although not yet complete, this clinical study provides new insights into the potential benefits of metformin use on right ventricular failure in patients with PH and indicates the need for more studies of the use of metformin therapeutic intervention in patients with PH and PH-HFpEF.

CONCLUSION AND PERSPECTIVES

In this review, we discussed some seemingly contradictory study results for AMPK and PH development. AMPK has a key role in PH, either during the early process of hypoxic pulmonary vasoconstriction or later during pulmonary vasculature remodeling, or both. However, whether AMPK activation or inhibition is protective against PH remains unclear: (1) AMPK activation triggers hypoxia-induced pulmonary artery constriction. AMPK activator use (e.g., AICAR and Ara-a) prevents hypoxia-induced pulmonary artery constriction and PH. (2) EC-specific deletion of AMPK exaggerates hypoxia-induced PH in vivo. This result indicates endothelial AMPK has a protective role during PH development. (3) VSMCs from large pulmonary arteries with AMPK activation have accelerated proliferation and inhibited apoptosis. VSMCs from distal small pulmonary arteries with AMPK inhibition have similar potential. (4) Some animal studies found that the AMPK activators, AICAR and metformin, have beneficial effects on PH treatment. Other study findings suggest that metformin therapy for PH may be limited to use for PH-HFpEF. AMPK activation might have less pronounced pulmonary vascular effects than right ventricular effects, as much evidence has been published suggesting that AMPK activation exerts a protective effect in cardiac dysfunction, ischemic heart, heat failure, and cardiac hypertrophy (Russell et al., 2004; Miller et al., 2008; Ma et al., 2010; Kim et al., 2011; Morrison et al., 2011). (5) Sex differences in the response to metformin used for PH treatment may affect outcomes.

In conclusion, studies found seemingly contradictory results for the relationship between AMPK and PH. In one series of studies, inhibition of AMPK resulted in attenuated hypoxic pulmonary vasoconstriction and pulmonary VSMC proliferation. In another series of studies, activation of AMPK resulted in improved EC function, VSMC apoptosis, and decreased pulmonary vasculature tone. Given that AMPK a1 and AMPK a2 have different expression patterns and different functions in pulmonary arteries of different sizes, the role of AMPK in PH should be studied using a cell-specific and pathological process-specific approach. Studies involving genetically- and specifically-modified AMPK a1 and a2 subunits are needed to clarify their specific roles in PH pathogenesis and treatment.

AUTHOR CONTRIBUTIONS

QZ drafted the manuscript and figures. PS and M-HZ revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported in part by National Heart, Lung, and Blood Institute (HL079584, HL080499, HL089920, HL110488, HL128014, HL132500, HL137371, and HL142287), National Cancer Institute (CA213022), and National Institute on Aging (AG047776) (to M-HZ) and HL140954 (PS). QZ is a recipient of Postdoctoral Fellowship Award of American Heart Association (835456).

REFERENCES

Afalayan, A. J., Eis, A., Alexander, M., Michalkiewicz, T., Teng, R.-I., Lakshminrusimha, S., et al. (2016). Decreased endothelial nitric oxide synthase expression and function contribute to impaired mitochondrial biogenesis and oxidative stress in fetal lambs with persistent pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 310, L40–L49.

Agard, C., Rolli-Derkinderen, M., Dumas-de-La-Roque, E., Rio, M., Sagan, C., Savineau, J. P., et al. (2009). Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br. J. Pharmacol. 158, 1285–1294. doi: 10.1111/j.1476-5381.2009.00445.x

Ahmad, F., Arad, M., Musi, N., He, H., Wolf, C., Branco, D., et al. (2005). Increased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy. Circulation 112, 3140–3148. doi: 10.1161/circulationaha.105.550806

Anisimov, V. N., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Tyndyk, M. L., Egormin, P. A., et al. (2010). Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129Sv mice. Aging (Albany N. Y.) 2, 945–958. doi: 10.18632/aging.100245

Arad, M., Seidman, C. E., and Seidman, J. G. (2007). AMP-activated protein kinase in the heart. Circulat. Res. 100, 474–488.

Archer, S., and Michelakis, E. (2002). The mechanism(s) of hypoxic pulmonary vasoconstriction: potassium channels redox O2 sensors, and controversies. Physiology 17, 131–137. doi: 10.1152/physiol.01388.2002

Attinì, T., Camidge, R., Newby, D. E., and Webb, D. J. (2005). Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart 91, 825–831. doi: 10.1136/hrt.2004.035991

Bando, H., Atsumi, T., Nishio, T., Niwa, H., Mishima, S., Shimizu, C., et al. (2005). Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin. Cancer Res. 11, 5784–5792. doi: 10.1158/1078-0432.ccr-05-0149

Bergeron, R., Ren, J. M., Cadman, K. S., Moore, I. K., Perret, P., Pypaert, M., et al. (2001). Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am. J. Physiol. Endocrinol. Metabol. 281, E1340–E1346.

Bergofsky, E. H., Holtzman, S., and Study, A. (1967). A study of the mechanisms involved in the pulmonary arterial pressor response to hypoxia. Circulat. Res. 20, 506–519. doi: 10.1161/01.res.20.5.506

Bigham, A. W., Julian, C. G., Wilson, M. J., Vargas, E., Browne, V. A., Shrivar, M. D., et al. (2014). Maternal PRKAA1 and EDNRA genotypes are associated with birth weight, and PRKAA1 with uterine artery diameter and metabolic
homeostasis at high altitude. Physiol. Genom. 46, 687–697. doi: 10.1152/physiogenomics.00063.2014
Bradford, J. R., and Dean, H. P. (1894). The pulmonary circulation. J. Physiol. 16, 34–158.25.
Bramante, C. T., Ingraham, N. E., Murray, T. A., Marmor, S., Hovetseren, S., Gronski, J., et al. (2021). Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. Lancet Health. Longev. 2, e34–e41.
Brittain, E. L., Niswender, K., Agrawal, V., Chen, X., Fan, R., Pugh, M. E., et al. (2020). Mechanistic phase II clinical trial of metformin in pulmonary arterial hypertension. J. Am. Heart Assoc. 9:e018349.
Brown-Séquard, C. E. (1871). On the production of haemorrhage, anemia, idema, and emphysema in the lungs by injuries to the base of the brain. Lancet 97:6. doi: 10.1016/s0140-6736(02)77570-7
Budhiraja, R., Tuder, R. M., and Hassoun, P. M. (2004). Endothelial dysfunction in pulmonary hypertension. Circulation 109, 159–165.
Bungard, D., Fuerth, B. J., Zeng, P.-Y., Faubert, B., Maas, N. L., Viollet, B., et al. (2010). Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science 329, 1201–1205. doi: 10.1126/science.1191241
Carling, D., Zamtit, V. A., and Hardie, D. G. (1987). A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett. 223, 217–222. doi: 10.1016/0014-5793(87)80292-2
Chandra, S. M., Razavi, H., Kim, J., Agrawal, R., Kundu, R. K., de Jesus Perez, V., et al. (2011). Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler. Thromb. Vasc. Biol. 31, 814–820. doi: 10.1161/atvbaha.110.219980
Chen, L., Xin, F.-J., Wang, J., Hu, J., Zhang, Y.-Y., Wan, S., et al. (2013). Conserved regulatory elements in AMPK. Nature 498, E8–E10.
Chen, M., Cai, H., Hu, Y., Wu, P., Fu, Y., Xu, X., et al. (2016). Salidroside exerts protective effects against chronic hypoxia-induced pulmonary arterial hypertension via AMPKα1-dependent pathways. Am. J. Transl. Res. 8, 12–27.
Chen, Z., Peng, I. C., Sun, W., Su, M. I., Hsu, P. H., Fu, Y., et al. (2009). AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser63. Circulat. Res. 104, 496–505. doi: 10.1161/circresaha.108.187567
Cheung, P. C., Salt, I. P., Davies, S. P., and Carling, D. (2000). Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem. J. 346(Pt 3), 659–669. doi: 10.1042/0264-6021:3460659
Choi, S.-L., Kim, S.-J., Lee, K.-T., Kim, J., Mu, J., Birnbaum, M. J., et al. (2001). The AMP-activated protein kinase underpins hypoxic pulmonary hypertension. Nat. Med. 7, 1219–1224. doi: 10.1038/9737
Cheung, P. C., Salt, I. P., Davies, S. P., and Carling, D. (2000). Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem. J. 346(Pt 3), 659–669. doi: 10.1042/0264-6021:3460659
Choi, S.-L., Kim, S.-J., Lee, K.-T., Kim, J., Mu, J., Birnbaum, M. J., et al. (2001). The regulation of AMP-activated protein kinase by H2O2. Biochem. Biophys. Res. Commun. 287, 92–97.
Colvin, K. L., and Yeager, M. E. (2014). Animal models of pulmonary hypertension: matching disease mechanisms to etiology of the human disease. J. Pulmon. Respirat. Med. 4:198.
Creighton, J., Jian, M., Sayner, S., Alexeyev, M., and Insel, P. A. (2011). Adenosine monophosphate-activated kinase alpha1 promotes endothelial barrier repair. FASEB J. 25, 3356–3365. doi: 10.1096/fj.10-179218
Dengler, F., and Gabel, G. (2019). The fast lane of hypoxic pulmonary hypertension: glucose transport is modulated via a HIF-hydroxylase-AMPK-axis in jejunum epithelium. Int. J. Mol. Sci. 20:4993. doi: 10.3390/ijms20204993
Detar, R. (1894). The pulmonary circulation. J. Physiol. 16, 34–158.25.
Dawson, C. A., Grimm, D. J., and Linehan, J. H. (2017). Effects of lung inflation on vasoconstriction and carotid body excitation by hypoxia in mammals. Eur. Respirat. J. 28, 545–560. doi: 10.1183/13993003.0203630
Day, E. A., Ford, J. R., and Steinberg, G. R. (2017). AMPK as a therapeutic target for treating metabolic diseases. Trends Endocrinol. Metabol. 28, 545–560. doi: 10.1016/j.tet.2017.05.004
De Theije, C., C. Schols, A., Lamers, W. H., Neumann, D., Kohler, S. E., and Langen, R. C. J. (2018). Hypoxia impairs adaptation of skeletal muscle protein turnover- and AMPK signaling during fasting-induced muscle atrophy. PLoS One 13, e0203630. doi: 10.1371/journal.pone.0203630
Dean, A., Nilsen, M., Loughlin, L., Salt, I. P., and MacLean, M. R. (2016). Metformin reverses development of pulmonary hypertension via aromatase inhibition. Hypertension 66, 446–454. doi: 10.1161/hypertensionaha.116.073533
increases mitochondrial biogenesis in glycolytic skeletal muscle. J. Biol. Chem. 283, 35724–35734. doi: 10.1074/jbc.m80578200
Gomez-Arroyo, J. G., Farkas, L., Alhusaini, A. A., Farkas, D., Krauskaus, D., Voelkel, N. F., et al. (2012). The monocrotaline model of pulmonary hypertension in perspective. Am. J. Physiol. Lung Cell. Mol. Physiol. 302, A38–A369.
Goncharov, D. A., Goncharova, E. A., Tofovic, S. P., Hu, J., Baust, J. J., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., Hardie, D. G. (2008). AMPK: a key regulator of energy balance in the single cell. Circulation 129, 864–874. doi: 10.1161/circulationaha.113.004581
Gowans, G. J., Hawley, S. A., Ross, F. A., and Hardie, D. G. (2013). AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab. 18, 556–566. doi: 10.1016/j.cmet.2013.08.019
Grimm, D. J., Dawson, C. A., Hakim, T. S., and Linehan, J. H. (1978). Pulmonary vasomotion and the distribution of vascular resistance in a dog lung lobe. J. Appl. Physiol. 45, 545–550. doi: 10.1152/jappl.1978.45.3.545
Gui, D., Cui, Z., Zhang, L., Yu, C., Yao, D., Xu, M., et al. (2017). Salidroside attenuates hypoxia-induced pulmonary arterial smooth muscle cell proliferation and apoptosis resistance by upregulating autophagy through the AMPK-mTOR-ULK1 pathway. BMC Pulmon. Med. 17:191.
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., et al. (2008). AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell. 30, 214–226. doi: 10.1016/j.molcel.2008.03.003
Hansmann, G., Wagner, R. A., Schellong, S., Perez, V. A. d., Urashima, T., Wang, L., et al. (2007). Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 115, 1275–1284. doi: 10.1161/circulationaha.106.663120
Hardie, D. G. (2008). AMPK: a key regulator of energy balance in the single cell and the whole organism. Int. J. Obes. 32, 57–512.
Hardie, D. G. (2013). AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62, 2164–2172. doi: 10.2337/db13-0368
Hardie, D. G., Carling, D., and Gamblin, S. J. (2011). AMP-activated protein kinase: also regulated by ADP? Trends Biochem. Sci. 36, 470–477. doi: 10.1016/j.tibs.2011.06.004
Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., et al. (2003). Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMPK-activated protein kinase cascade. J. Biol. 2:28.
Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., et al. (2005). Calmodulin-dependent protein kinase kinase-2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension. Circulation 129, 864–874. doi: 10.1161/circulationaha.113.004581
Ke, R., Liu, L., Zhu, Y., Li, S., Xie, X., Li, F., et al. (2016). Knockdown of AMPKα2 promotes pulmonary arterial smooth muscle cells proliferation via mTOR/Skp2/p27(Kip1) signaling pathway. Int. J. Mol. Sci. 17:844. doi: 10.3390/ijms17060844
Kelly, M., Keller, C., Avilucea, P. R., Keller, P., Luo, Z., Xiang, X., et al. (2004). AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem. Biophys. Res. Commun. 320, 449–454. doi: 10.1016/j.bbrc.2004.05.188
Kemp, B. E. (2004). Bateman domains and adenosine derivatives form a binding contract. J. Clin. Investigat. 113, 182–184. doi: 10.1122/jc.200420846
Kim, A. S., Miller, E. I., Wright, T. M., Li, J., Qi, D., Atsina, K., et al. (2011). A small molecule AMPK activator protects the heart against ischemia–reperfusion injury. J. Mol. Cell. Cardiol. 51, 24–32. doi: 10.1016/j.yjmcc.2011.03.003
Kim, E. K., Lee, J. H., Oh, Y. M., Lee, Y. S., and Lee, S. D. (2010). Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats. Respiratio (Carlton Vic.) 15, 659–668. doi: 10.1111/j.1440-1843.2010.01756.x
Kim, J. (2014). Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension. Mol. Cell. 37, 196–201. doi: 10.1038/molecularcells.2014.12308
Kim, J., Yang, G., Kim, Y., Kim, J., and Ha, J. (2016). AMPK activators: mechanisms of action and physiological activities. Exp. Mol. Med. 48:e224. doi: 10.1038/emm.2016.16
Klinger, J. R., Abman, S. H., and Gladwin, M. T. (2013). Nitric oxide and S-nitrosothiol deficiency in pulmonary hypertension: A theoretical and experimental perspective. Front. Physiol. 4:207. doi: 10.3389/fphys.2013.00207
Kloos, B. (2008). Role of AMP-activated protein kinase in the control of appetite. J. Neuroendocrinol. 20, 942–951. doi: 10.1111/j.1365-2826.2008.01745.x
Kolb, B., Hubina, E., Tucci, S. A., Kirkham, T. C., Garcia, E. A., Mitchell, S. E., et al. (2005). Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J. Biol. Chem. 280, 25196–25201. doi: 10.1074/jbc.m500175200
Luo, Z., Church, D. M., and Voelkel, N. F., et al. (2012). The monocrotaline model of pulmonary hypertension: state of the art and research perspectives. Eur. Respir. J. 53:1801887. doi: 10.1183/13993003.01887-2010
Miyata, M., Guignabert, C., Bonnet, S., Dorfmüller, P., Klinger, J. R., Nicolls, M. R., et al. (2019). Pathology and pathobiology of pulmonary hypertension: 2019 update. J. Pathol. Assess. 7, 121. doi: 10.1111/jpa.12744
Niko, K., Zhu, T., and Guan, K.-L. (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577–590. doi: 10.1016/s0092-8674(03)00929-2
Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., et al. (2005). AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell. 30, 214–226. doi: 10.1016/j.molcel.2008.03.003
Park, J. Y., Oh, Y. H., Kim, J., and Kim, E. S. (2004). AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem. Biophys. Res. Commun. 320, 449–454. doi: 10.1016/j.bbrc.2004.05.188
Pepicelli, F., Zuffa, F., Corbo, S., and Zoccali, C. (2004). AMPK: a key regulatory element in the pathology of hypertensive pulmonary arterial hypertension. J. Renin. Angiop. 2004.05.188
Koo, S.-H., Flechner, L., Qi, L., Zhang, X., Scraton, R. A., Jeffries, S., et al. (2005). The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437, 1109–1114. doi: 10.1038/nature03967

Krymskaya, V. P., Snow, J., Cesarone, G., Khavkin, I., Goncharov, D. A., Lim, P. N., et al. (2011). mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J. 25, 1922–1933. doi: 10.1096/fj.10-175018

Lai, Y. C., Tabima, D. M., Dube, J. J., Hughan, K. S., Vanderpool, R. R., Goncharov, D. A., et al. (2016). ESIR3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction. Circulation 133, 717–731. doi: 10.1161/circulationaha.115.018935

Lamia, K. A., Sachdeva, U. M., DiTacchio, L., Williams, E. C., Alvarez, J. G., Koo, S.-H., Flechner, L., Qi, L., Zhang, X., Screaton, R. A., Jeffries, S., et al. (2005). A new constitutively active mutant of AMP-activated protein kinase in the ischaemic heart. Nature 431, 578–582. doi: 10.1038/nature06954

Mihaylova, M. M., and Shaw, R. J. (2011). The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell. Biol. 13, 1016–1023. doi: 10.1038/ncb2329

Miller, E. J., Li, J., Leng, L., McDonald, C., Atsumi, T., Bucala, R., et al. (2008). Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the myocardium. Circulation 119, 285–295. doi: 10.1161/circulationaha.115.018935

Moral-Sanz, J., Lewis, S. A., MacMillan, S., Ross, F. A., Thomson, A., Violett, B., et al. (2018). The LKB1–AMPKα1 signaling pathway triggers hypoxic pulmonary vasoconstriction downstream of mitochondrial. Sci. Signal. 11:0296.

Mourad, S. N., Mahmoud, A. D., Ross, F. A., Eldstrom, J., Fedida, D., Hardie, D. G., et al. (2016). AMP-activated protein kinase inhibits Kv1.5 channel currents of pulmonary arterial myocytes in response to hypoxia and inhibition of mitochondrial oxidative phosphorylation. J. Physiol. 594, 4901–4915. doi: 10.1113/jp272032

Nicolls, M. R., and Voelkel, N. F. (2017). The roles of immunity in the prevention of pulmonary arterial hypertension in the contemporary era: a review. Thorac. Res. 1, 1056–1065. doi: 10.1183/23120541.00060-2018

Oakhill, J. S., Scott, J. W., and Kemp, B. E. (2012). AMPK functions as an adenylate charge-regulated protein kinase. Trends Endocrinol. Metabol. 23, 125–132. doi: 10.1016/j.tem.2011.12.006

Zhang et al.
Sakamoto, K., McCarthy, A., Smith, D., Green, K. A., Hardie, D. G., Ashworth, A., Ryan, J. J., Marsboom, G., and Archer, S. L. (2013). Rodent models of group 1 Robertson, T. P., Mustard, K. J., Lewis, T. H., Clark, J. H., Wyatt, C. N., Blanco, Russell, R. R. I. I. I., Li, J., Coven, D. L., Pypaert, M., Zechner, C., Ross, F. A., MacKintosh, C., and Hardie, D. G. (2016b). AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. "3001. doi: 10.1116/jb.phrs.2017.08.003 Stapleton, D., Mitchell, K. I., Gao, G., Widmer, J., Michell, B. J., Teh, T., et al. (1996). Mammalian AMP-activated protein kinase subfamily. J. Biol. Chem. 271, 611–6114. Steinmark, K. R., and McMurtry, I. F. (2005). Vascular remodeling versus vasocostriction in chronic hypoxic pulmonary hypertension. Circ. Res. 97, 95–98. doi: 10.1161/01.res.00000175934.68087.29 Steinmark, K. R., Fagan, K. A., and Frid, M. G. (2006). Hypoxia-induced pulmonary vascular remodeling. Circulat. Res. 99, 675–691. Sun, Z., Liu, Y., Yu, F., Xu, Y., Yanli, L., and Liu, N. (2019). Long non-coding RNA and mRNA profile analysis of metformin to reverse the pulmonary hypertension vascular remodeling induced by monocrotaline. Biomol. Ther. 115:10893. doi: 10.1016/j.biopha.2019.108933 Sylvester, T. J., Shimoda, L. A., Aaronson, P. I., and Ward, J. P. T. (2012). Hypoxic pulmonary vasocostriction. Physiol. Rev. 92, 367–520. Sztuka, K., and Jasinski-Stroschein, M. (2017). Animal models of pulmonary arterial hypertension: a systematic review and meta-analysis of data from 6126 Omura, J., Satoh, K., Kikuchi, N., Satoh, T., Kuroswawa, R., Nogi, M., et al. (2016). Protective roles of endothelial AMP-activated protein kinase against hypoxia-induced pulmonary hypertension in mice. Circulat. Res. 119, 197–209. doi: 10.1161/circressa.115.308187 Park, J. W., Lee, J. H., Park, Y. H., Park, S. J., Cheon, J. H., Kim, W. H., et al. (2017). Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients. World J. Gastroentro. 23, 5196–5205. doi: 10.3748/wjg.v23.i12.5196 Penaloza, D., and Arias-Stella, J. (2007). The heart and pulmonary circulation at high altitudes. Circulat. Res. 115, 1132–1146. doi: 10.1161/circulationaha.106.624544 Plevitá-Hlavatá, L., Tauber, J., Li, M., Zhang, H., Flockton, A. R., et al. (2006). Deficiency of LKB1 in heart prevents ischemia-mediated cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 20, 427–438. doi: 10.1096/fj.06-3043comurry, D., and Powell, M. (2017). Hypoxic pulmonary vasoconstriction. BJU Educat. 17, 208–213.
Wang, Z., Wilson, W. A., Fujino, M. A., and Roach, P. J. (2001). Antagonistic
Frontiers in Cell and Developmental Biology | www.frontiersin.org
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G., Neumann,
Thenappan, T., Shah, S. J., Gomberg-Maitland, M., Collander, B., Vallakati, A.,
Shroff, P., et al. (2011). Clinical characteristics of pulmonary hypertension in
patients with heart failure and preserved ejection fraction. Circulat. Heart Fail.
4, 257–265.
Thomson, D. M., Porter, B. B., Tall, J. H., Kim, H.-J., Barrow, J. R., and
Winder, W. W. (2007). Skeletal muscle and heart LKB1 deficiency causes
decreased voluntary running and reduced muscle mitochondrial marker
enzyme expression in mice. Am. J. Physiol. Endocrinol. Metab. 292, E196–E202.
Towler, M. C. and Hardie, D. G. (2007). AMP-activated
protein kinase in metabolic control and insulin signaling. Circulat. Res.
100, 328–341. doi: 10.1161/01.res.0000256090.42690.05
Toyama, E. Q., Herzig, S., Courchet, J., Lewis, T. L., Loson, O. C., Hellberg, K.,
et al. (2016). AMP-activated protein kinase mediates mitochondrial fission
in response to energy stress. Science 351, 275–281. doi: 10.1126/science.aab4138
Tuder, R. M. (2017). Pulmonary vascular remodeling in pulmonary hypertension.
Cell Tissue Res. 367, 643–649.
Tuder, R. M., Marecki, J. C., Richter, A., Fijalkowska, I., and Flores, S. (2007).
Pathology of pulmonary hypertension. Clin. Chest Med. 28, 23–vii.
Violet, B., Lantier, L., Devin-Leclerc, J., Hebrard, S., Amouyel, C., Mounier, R.,
et al. (2009). Targeting the AMPK pathway for the treatment of Type 2 diabetes.
Front. Biosci. (Landmark Ed.) 14:3380–3400. doi: 10.2741/3460
von Euler, U. S., and von Liljestrand, G. (1946). Observations on the pulmonary
arterial blood pressure in the act. Physiol. Scandinav. 12, 301–320. doi:
10.1111/j.1744-1716.1946.tb00389.x
Wang, L., Halliday, G., Huot, J. R., Satoh, T., Baust, J. J., Fisher, A., et al. (2020).
The mechanism of acute hypoxic pulmonary vasoconstriction: the tale of two channels.
Respirat. Mol. Cell. Biol. 28, 23–vii.
Xia, B., Heath, R., Saiu, P., Leiper, F. C., Leone, P., Jing, C., et al. (2007). Structural
basis for AMP binding to mammalian AMP-activated protein kinase. Nature
449, 496–500. doi: 10.1038/nature06161
Xiao, B., Sanders, M. J., Underwood, E., Heath, R., Mayer, F. V., Carmena, D., et al.
(2011). Structure of mammalian AMPK and its regulation by ADP. Nature 472,
230–233. doi: 10.1038/nature09932
Xue, J., Nelin, L. D., and Chen, B. (2017). Hypoxia induces arginase II expression
and increases viable human pulmonary artery smooth muscle cell numbers via AMPKα1 signaling. Am. J. Physiol. Lung Cell. Mol. Physiol. 312, L568–L578.
Yan, H., Zhang, D. X., Shi, X., Zhang, Q., and Huang, Y. S. (2012). Activation of the
prolyl-hydroxylation oxygen-sensing signal cascade leads to AMPK activation in
cardiomyocytes. J. Cell. Mol. Med. 16, 2049–2059. doi: 10.1111/j.1582-4934.
2011.01500.x
Yan, Y., Zhou, X. E., Xu, H. E., and Melcher, K. (2018). Structure and physiological
regulation of AMPK. Int. J. Mol. Cell. Sci. 19:3534. doi: 10.3390/ijms19113534
Yoshida, T., Matsuura, K., Goya, S., Ma, D., Shimada, K., Kitipatpuk, P., et al.
(2020). Metformin prevents the development of monocrotaline-induced pulmonary hypertension by decreasing serum levels of big endothelin-1. Exp.
Therap. Med. 10:149.
Yuan, J. X.-L., Aldinger, A. M., Juhászova, M., Wang, J., Conte, J. V., Gaine, S. P.,
et al. (1998). Dysfunctional voltage-gated K+ channels in pulmonary artery smooth
muscle cells of patients with primary pulmonary hypertension. Circulat. Res.
94, 1400–1406. doi: 10.1161/01.res.94.14.1400
Zarrinpashneh, E., Carvalja, K., Beauloye, C., Ginion, A., Mateo, P., Pouleur, A.-
C., et al. (2006). Role of the α2-isofrom of AMP-activated protein kinase in the
metabolic response of the heart to no-flow ischemia. Am. J. Physiol. Heart Circulat.
Physiol. 291, H2875–H2883.
Zhai, C., Shi, W., Feng, W., Zhu, Y., Wang, J., Li, S., et al. (2018). Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation. Life Sci. 208, 87–95. doi:
10.1016/j.lfs.2018.07.018
Zhang, J., Dong, J., Martin, M., He, M., Gongol, B., Marin, T. L., et al. (2018).
Shy AMP-activated protein kinase phosphorylation of angiotensin-converting
enzyme 2 in endothelium mitigates pulmonary hypertension. Am. J. Respirat.
Crit. Care Med. 198, 509–520. doi: 10.1164/rccm.201712-2570oc
Zhang, Y., Lee, T. S., Kolb, E. M., Sun, K., Lu, X., Sladek, F. M., et al. (2006).
AMP-activated protein kinase is involved in endothelial NO synthase activation
in response to shear stress. Arterioscler. Thromb. Vasc. Biol. 26, 1281–1287. doi:
10.1161/ATVBAHA.105.472016
Zhao, F., Wang, C., and Zhu, X. (2020). Isoform-specific roles of AMPK catalytic
α subunits in Alzheimer’s disease. J. Clin. Investigat. 130, 3403–3405. doi:
10.1172/jci137908
Zhao, L. (2010). Chronic hypoxia-induced pulmonary hypertension in rat: the best
animal model for studying pulmonary vasoconstriction and vascular medial
hypertrophy. Drug Discover. Today Dis. Models 7, 83–88.
Zmijewski, J. W., Banerjee, S., Bae, H., Friggeri, A., Lazarowski, E. R., and
Abraham, E. (2010). Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinase. J. Biol. Chem. 285, 33154–33164. doi:
10.1074/jbc.m110.143685
Zong, H., Ren, J. M., Young, L. H., Pypaert, M., Mu, J., Birnbaum, M. J., et al.
(2002). AMP kinase is required for mitochondrial biogenesis in skeletal muscle
in response to chronic energy deprivation. Proc. Natl. Acad. Sci. U.S.A. 99,
15983–15987. doi: 10.1073/pnas.252625599
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Zhao, Song and Zou. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.